{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-22-000005","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.546463+00:00","generated_at":"2026-06-27T11:29:12.236210+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CFO Elaine Sun steps down; Nicole LaBrosse appointed effective Feb 2, 2022","bullets":["Elaine Sun left immediately to pursue another opportunity; separation agreement expected.","Nicole LaBrosse, previously VP Finance and Accounting since 2020, named CFO.","LaBrosse's initial base salary set at $485,500 with 45% bonus target.","LaBrosse has 18+ years of public accounting and corporate finance experience, including at PwC.","CEO Dr. Helen Torley highlighted LaBrosse's internal knowledge and financial skill set."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-22-000005","json":"https://secwatch.observer/filing/0001159036-22-000005.json","markdown":"https://secwatch.observer/filing/0001159036-22-000005.md","text":"https://secwatch.observer/filing/0001159036-22-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/halo-20220202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:29:12.236210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86eecd123c","claim":"Elaine Sun departed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"beff4ad359","claim":"Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}